by Steven Hatfill
August 04,
2020
from
RealClearPolitics Website
Steven Hatfill is a
veteran virologist who helped establish the Rapid
Hemorrhagic Fever Response Teams for the National
Medical Disaster Unit in Kenya, Africa.
He is an adjunct
assistant professor in two departments at the George
Washington University Medical Center where he teaches
mass casualty medicine.
He is principle author of the
prophetic book
"Three Seconds Until Midnight - Preparing
for the Next Pandemic," published by Amazon in 2019. |
Adobe Stock
It is Technocrats like Anthony Fauci who originally
fomented the war against HCQ and they blocked its
use at every turn.
All testimony by MDs and scientists supporting HCQ
is summarily ridiculed and dismissed.
Tens of thousands of people have needlessly died
because of these mean-spirited policies by Big
Pharma to protect the deployment of their expensive
drugs and vaccines.
Source
An Effective
COVID Treatment the Media Continues to Besmirch
On Friday, July 31, in a column ostensibly dealing with health care
"misinformation," Washington Post media 'critic'
Margaret Sullivan opened by
lambasting,
"fringe doctors
spouting dangerous falsehoods about hydroxychloroquine as a
COVID-19 wonder cure."
Actually, it was Sullivan
who was spouting dangerous falsehoods about this drug, something the
Washington Post and much of the rest of the media have been
doing for months.
On May 15, the Post
offered a stark warning to any Americans who may have taken hope in
a possible therapy for COVID-19. In the newspaper's telling, there
was nothing unambiguous about the science - or the politics - of
hydroxychloroquine:
"Drug promoted by
Trump as coronavirus game-changer increasingly linked to
deaths," blared the headline.
Written by three Post
staff writers, the story asserted that the effectiveness of
hydroxychloroquine in treating
COVID-19 is scant and that the drug is inherently 'unsafe'...
This claim is
nonsense...
Biased against the
use of hydroxychloroquine for COVID-19 - and the Washington Post
is hardly alone - the paper described an April 21, 2020, drug
study on U.S. Veterans Affairs patients hospitalized with the
illness.
It found a
'high death rate' in patients taking the drug
hydroxychloroquine...
But this was a
flawed study with a small sample, the main flaw being
that,
the drug was
given to the sickest patients who were already dying because of
their age and severe pre-existing conditions...
This study was
quickly debunked.
It had been posted
on a non-peer-reviewed medical archive that specifically warns that
studies posted on its website should not be
reported in the media as
established information.
Yet, the Post and
countless other news outlets did just the opposite, making repeated
claims that hydroxychloroquine was ineffective and caused
serious cardiac problems.
Nowhere was
there any mention of the fact that COVID-19 damages the heart
during infection, sometimes causing irregular and sometimes
fatal heart rhythms in patients not taking the drug.
To a media
unrelentingly hostile to
Donald Trump, this meant that
the president could be portrayed as recklessly promoting the use of
a "dangerous" drug.
Ignoring the
refutation of the VA study in its May 15 article, the Washington
Post cited a Brazil study published on April 24 in which a COVID
trial using chloroquine (a related but different
drug than
hydroxychloroquine) was stopped
because 11 patients treated with it died.
The reporters never
mentioned another problem with that study:
The Brazilian
doctors were giving their patients lethal cumulative doses of
the drug...
On and on it has
gone since then, in a circle of self-reinforcing commentary.
Following the news
that Trump was taking the drug himself, opinion hosts on cable news
channels launched continual attacks on both hydroxychloroquine and
the president.
"This will kill
you!" Fox News Channel's Neil Cavuto exclaimed.
"The president
of the United States just acknowledge that he is taking
hydroxychloroquine, a drug that [was] meant really to treat
malaria and lupus."
Washington Post
reporters
Ariana Cha and
Laurie McGinley were back again on May 22, with a new
article shouting out the new supposed news:
"Antimalarial
drug touted by President Trump is linked to increased risk of
death in coronavirus patients, study says."
The media uproar
this time was based on a large study just published in the Lancet.
There was just one
problem.
The Lancet
paper
was fraudulent and it was quickly retracted...
However, the damage
from the biased media storm was done and it was long-lasting.
Continuing patient
enrollment needed for early-use clinical trials of
hydroxychloroquine dried up within a week:
-
patients
were afraid to take the drug
-
doctors
became afraid to prescribe it
-
pharmacies
refused to fill prescriptions,
...and
in a rush of incompetent analysis and non-existent senior
leadership,
the FDA revoked its Emergency
Use Authorization for the drug.
So what is the
real story on hydroxychloroquine?
Here, briefly, is what we know:
When the
COVID-19 pandemic began, a search was made for suitable
antiviral therapies to use as treatment until a vaccine could be
produced.
One drug,
hydroxychloroquine, was found
to be the most effective and safe for use against the virus.
Federal funds
were used for clinical trials of it, but there was no guidance
from Dr.
Anthony Fauci or the
NIH Treatment Guidelines
Panel on what role the drug would play in the national
pandemic response.
Fauci seemed to
be unaware that there actually was a national pandemic plan for
respiratory viruses.
Following a
careful regimen developed by doctors in France, some
knowledgeable practicing U.S. physicians began prescribing
hydroxychloroquine to patients still in the
early
phase of COVID infection.
Its effects seemed dramatic.
Patients still
became sick, but for the most part they avoided hospitalization.
In contrast -
and in error - the NIH-funded studies somehow became focused on
giving hydroxychloroquine to late-presenting hospitalized
patients.
This was in
spite of the fact that unlike the drug's early use in ambulatory
patients, there was no real data to support the drug's use in
more severe hospitalized patients.
By April, it
was clear that roughly seven days from the time of the first
onset of symptoms, a COVID-19 infection could sometimes progress
into a more radical late phase of severe disease with
inflammation of the blood vessels in the body and immune system
over-reactions.
Many patients
developed blood clots in their lungs and needed mechanical
ventilation.
Some needed
kidney dialysis. In light of this pathological carnage, no
antiviral drug could be expected to show much of an effect
during this severe second stage of COVID.
On
April 6, 2020,
an international team of medical experts published an extensive
study of hydroxychloroquine in more than 130,000 patients with
connective tissue disorders.
They
reaffirmed that hydroxychloroquine was a safe drug with no
serious side effects...
The drug
could safely be given to pregnant women and breast-feeding
mothers.
Consequently,
countries such as,
China,
Turkey, South Korea, India, Morocco, Algeria, and others,
...began
to use hydroxychloroquine widely and early in their national
pandemic response.
Doctors
overseas were safely prescribing the drug based on clinical
signs and symptoms because widespread testing was not available.
However, the
NIH promoted a much different strategy for the United States.
The "Fauci
Strategy" was to keep early infected patients quarantined at
home without treatment until they developed a shortness of
breath and had to be admitted to a hospital.
Then they would
they be given hydroxychloroquine.
The Food and
Drug Administration cluelessly agreed to this doctrine and
it stated in its hydroxychloroquine Emergency Use
Authorization (EUA) that,
"hospitalized patients were likely to have a greater
prospect of benefit (compared to ambulatory patients with
mild illness)."
In reality just
the opposite was true...
This was a
tragic mistake by Fauci and FDA Commissioner Dr.
Stephen Hahn and it was a
mistake that would cost the lives of thousands of Americans in
the days to come.
At the same
time, accumulating data showed remarkable results if
hydroxychloroquine were given to patients early, during a
seven-day window from the time of first symptom onset.
If given during
this window, most infections did not progress into the severe,
lethal second stage of the disease.
Patients still
got sick, but they avoided hospitalization or the later transfer
to an intensive care unit.
In mid-April a
high-level memo was sent to the FDA alerting them to the fact
that the best use for hydroxychloroquine was for its early use
in still ambulatory COVID patients.
These patients
were quarantined at home but were not short of breath and did
not yet require supplemental oxygen and hospitalization.
Failing to
understand that COVID-19 could be a two-stage disease process,
the FDA ignored the memo and, as previously mentioned, it
withdrew its EUA for hydroxychloroquine based on flawed studies
and clinical trials that were applicable only to late-stage
COVID patients.
By now,
however, some countries had already implemented early,
aggressive, outpatient community treatment with
hydroxychloroquine and within weeks were able to minimize their
COVID deaths and bring their national pandemic under some degree
of control.
In countries such
as Great Britain and the United States, where the "Fauci-Hahn
Strategy" was followed, there was a much higher death rate and
an ever-increasing number of cases.
COVID patients
in the U.S. would continue to be quarantined at home and left
untreated until they developed shortness of breath.
Then they would
be admitted to the hospital and given hydroxychloroquine outside
the narrow window for the drug's maximum effectiveness.
In further
contrast, countries that started out with the "Fauci-Hahn
Doctrine" and then later shifted their policy towards aggressive
outpatient hydroxychloroquine use, after a brief lag period also
saw a stunning rapid reduction in COVID mortality and hospital
admissions.
Finally,
several nations that had started using an aggressive early-use
outpatient policy for hydroxychloroquine, including France
and Switzerland, stopped this practice when the WHO
temporarily withdrew its support for the drug.
Five days after
the publication of the fake Lancet study and the
resulting media onslaught, Swiss politicians banned
hydroxychloroquine use in the country from May 27
until June 11, when it was quickly reinstated...
The consequences of
suddenly stopping hydroxychloroquine can be seen by examining a
graph of the Case Fatality Ratio Index (nrCFR)
for Switzerland.
This is derived by
dividing the number of daily new COVID fatalities by the new cases
resolved over a period with a seven-day moving average.
Looking at the
evolution curve of the CFR it can be seen that during the weeks
preceding the ban on hydroxychloroquine, the nrCFR
index fluctuated between 3% and 5%.
Following a lag of
13 days after stopping outpatient hydroxychloroquine use, the
country's COVID-19 deaths increased four-fold and the
nrCFR index stayed elevated at
the highest level it had been since early in the COVID pandemic,
oscillating at over 10%-15%.
Early outpatient
hydroxychloroquine was restarted June 11 but the four-fold "wave of
excess lethality" lasted until June 22, after which the nrCFR
rapidly returned to its background value.
Here in our
country, Fauci continued to ignore the ever accumulating and
remarkable early-use data on hydroxychloroquine and he became
focused on a new antiviral compound named remdesivir.
This was an
experimental drug that had to be given intravenously every day for
five days. It was never suitable for major widespread outpatient or
at-home use as part of a national pandemic plan.
We now know now
that remdesivir has no effect on overall COVID
patient mortality and it costs thousands of dollars per patient.
Hydroxychloroquine,
by contrast, costs 60 cents a tablet, it can be taken at
home, it fits in with the national pandemic plan for respiratory
viruses, and a course of therapy simply requires swallowing three
tablets in the first 24 hours followed by one tablet every 12 hours
for five days.
There are now
53 studies that show positive results of hydroxychloroquine in
COVID infections.
There are 14
global studies that show neutral or negative results - and 10 of
them were of patients in very late stages of COVID-19, where no
antiviral drug can be expected to have much effect.
Of the
remaining four studies, two come from the same University of
Minnesota author.
The other two
are from the faulty Brazil paper, which should be retracted, and
the fake Lancet paper, which was.
Millions of people
are taking or have taken hydroxychloroquine in nations that have
managed to get their national pandemic under some degree of control.
Two recent, large,
early-use clinical trials have been conducted by the Henry Ford
Health System and at Mount Sinai showing a 51% and 47%
lower mortality, respectively, in hospitalized patients given
hydroxychloroquine.
A recent study from
Spain published on July 29, two days before Margaret Sullivan's
strafing of "fringe doctors," shows a 66% reduction in COVID
mortality in patients taking hydroxychloroquine.
No serious side
effects were reported in these studies and no epidemic of
heartbeat abnormalities.
This is
ground-shaking news.
Why is it not
being widely reported?
Why is the
American
media trying to run the U.S.
pandemic response with its own misinformation...?
|